1.Nasiri Toosi M, Shams Ardekani MR, Minaie MB, Nazim I,
Esfahani MM, Khadem A. Fatty Liver Disease From the
Perspective of Traditional Iranian Medicine. Quran Med.
2012;1(4):117-8. doi: 10.5812/quranmed.11092
2. Savadkooh F, Hosseini Tabatabai M, Shahabinejad S. [The
prevalence of fatty liver on ultrasound patients without a
history of liver disease and its association with cholesterol and
triglyceride]. TabibShargh. 2003;5(3):177-83.
3. Orangi E, Ostadrahimi A, Mahdavi R, Svmy M, Tarzmani M.
[Indicators related to oxidative stress and antioxidant status in
patients with nonalcoholic fatty liver]. J EndocrinolMetab.
2010;12(5):499-3.
4. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash
CRN. The association of genetic variability in patatin-like
phospholipase domain-containing protein 3 (PNPLA3) with
histological severity of nonalcoholic fatty liver disease.
Hepatology. 2010;52(3):894-903. doi: 10.1002/hep.23759
pmid: 20684021
5. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio
A, et al. I148M patatin-like phospholipase domain-containing
3 gene variant and severity of pediatric nonalcoholic fatty liver
disease. Hepatology. 2010;52(4):1274-80. doi:
10.1002/hep.23823 pmid: 20648474
6. Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu
RC, et al. A multi-ethnic study of a PNPLA3 gene variant and
its association with disease severity in non-alcoholic fatty liver
disease. Hum Genet. 2012;131(7):1145-52. doi:
10.1007/s00439-012-1141-y pmid: 22258181
7. Romeo S, Huang-Doran I, Baroni MG, Kotronen A.
Unravelling the pathogenesis of fatty liver disease: patatin-like
phospholipase domain-containing 3 protein. Curr Opin
Lipidol. 2010;21(3):247-52. doi:
10.1097/mol.0b013e328338ca61 pmid: 20480550
8. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K,
Bergholm R, Johansson LM, et al. Prediction of non-alcoholic
fatty liver disease and liver fat using metabolic and genetic
factors. Gastroenterology. 2009;137(3):865-72. doi:
10.1053/j.gastro.2009.06.005 pmid: 19524579
9. Sohrabpour AA, Rezvan H, Amini-Kafiabad S, Dayhim M,
Merat S, Pourshams A. Prevalence of nonalcoholic
steatohepatitis in Iran: a population based study. Middle East J
Digest Dis. 2010;2(1):14.
10. Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan
G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence
among school-aged children and adolescents in Iran and its
association with biochemical and anthropometric measures.
Liver Int. 2009;29(2):159-63. doi: 10.1111/j.1478-
3231.2008.01790.x pmid: 18492015
11. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M,
Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in
southern Iran: a population based study. Hepat Mon.
2013;13(5):e9248. doi: 10.5812/hepatmon.9248 pmid:
23922564
12. Baulande S, Lasnier F, Lucas M, Pairault J. Adiponutrin, a
transmembrane protein corresponding to a novel dietary- and
obesity-linked mRNA specifically expressed in the adipose
lineage. J Biol Chem. 2001;276(36):33336-44. doi:
10.1074/jbc.M105193200 pmid: 11431482
13. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D,
Pennacchio LA, et al. Genetic variation in PNPLA3 confers
susceptibility to nonalcoholic fatty liver disease. Nat Genet.
2008;40(12):1461-5. doi: 10.1038/ng.257 pmid: 18820647
14. Sanyal AJ, American Gastroenterological A. AGA technical
review on nonalcoholic fatty liver disease. Gastroenterology.
2002;123(5):1705-25. doi: 10.1053/gast.2002.36572 pmid:
12404245
15. Chang CY. Understanding the relationship between PNPLA3,
NAFLD and insulin resistance: do ethnic differences bring
more questions or more answers? Liver Int. 2011;31(9):1246-
9. doi: 10.1111/j.1478-3231.2011.02612.x pmid: 22093451
16. Li Q, Qu HQ, Rentfro AR, Grove ML, Mirza S, Lu Y, et al.
PNPLA3 polymorphisms and liver aminotransferase levels in a
Mexican American population. Clin Invest Med.
2012;35(4):E237-45. doi: 10.25011/cim.v35i4.17153 pmid:
22863562